Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Short

Showing results (541-550 of 659) with videos related to

Pageof 66
Sort By:
British Journal of Haematology|February 22, 2021
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemiaSanam Loghavi, Courtney D DiNardo, Ken Furudate, et al.
Cancer|August 2, 2016
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysisKoji Sasaki, Elias J Jabbour, Farhad Ravandi, et al.
Blood Cancer Journal|May 28, 2020
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALLNicholas J Short, Hagop Kantarjian, Rashmi Kanagal-Shamanna, et al.
The Lancet. Haematology|May 15, 2023
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trialElias Jabbour, Nicholas J Short, Jayastu Senapati, et al.
Cancer|June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageGeorgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
American Journal of Hematology|June 26, 2019
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibFevzi Yalniz, Iman Abou Dalle, Hagop Kantarjian, et al.
American Journal of Hematology|September 10, 2022
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemiaSangeetha Venugopal, Courtney D DiNardo, Sanam Loghavi, et al.
Blood Advances|September 15, 2021
Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experienceGuillaume Richard-Carpentier, Hagop M Kantarjian, Guilin Tang, et al.
Cancer|August 11, 2016
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemiaNicholas J Short, Hagop M Kantarjian, Koji Sasaki, et al.
Blood Advances|April 24, 2020
Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemiaNicholas J Short, Keyur P Patel, Maher Albitar, et al.
Pageof 66

Showing results (541-550 of 659) with videos related to

Sort By:
Pageof 66
British Journal of Haematology|February 22, 2021
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemiaSanam Loghavi, Courtney D DiNardo, Ken Furudate, et al.
Cancer|August 2, 2016
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysisKoji Sasaki, Elias J Jabbour, Farhad Ravandi, et al.
Blood Cancer Journal|May 28, 2020
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALLNicholas J Short, Hagop Kantarjian, Rashmi Kanagal-Shamanna, et al.
The Lancet. Haematology|May 15, 2023
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trialElias Jabbour, Nicholas J Short, Jayastu Senapati, et al.
Cancer|June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageGeorgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
American Journal of Hematology|June 26, 2019
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibFevzi Yalniz, Iman Abou Dalle, Hagop Kantarjian, et al.
American Journal of Hematology|September 10, 2022
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemiaSangeetha Venugopal, Courtney D DiNardo, Sanam Loghavi, et al.
Blood Advances|September 15, 2021
Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experienceGuillaume Richard-Carpentier, Hagop M Kantarjian, Guilin Tang, et al.
Cancer|August 11, 2016
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemiaNicholas J Short, Hagop M Kantarjian, Koji Sasaki, et al.
Blood Advances|April 24, 2020
Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemiaNicholas J Short, Keyur P Patel, Maher Albitar, et al.
Pageof 66